EIF1AX and NRAS mutations co-occur and cooperate in low-grade serous ovarian carcinomas

70Citations
Citations of this article
55Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Low-grade serous ovarian carcinomas (LGSC) are associated with a poor response to chemotherapy and are molecularly characterized by RAS pathway activation. Using exome and whole genome sequencing, we identified recurrent mutations in the protein translational regulator EIF1AX and in NF1, USP9X, KRAS, BRAF, and NRAS. RAS pathway mutations were mutually exclusive; however, we found significant co-occurrence of mutations in NRAS and EIF1AX. Missense EIF1AX mutations were clustered at the N-terminus of the protein in a region associated with its role in ensuring translational initiation fidelity. Coexpression of mutant NRAS and EIF1AX proteins promoted proliferation and clonogenic survival in LGSC cells, providing the first example of co-occurring, growth-promoting mutational events in ovarian cancer.

Cite

CITATION STYLE

APA

Etemadmoghadam, D., Azar, W. J., Lei, Y., Moujaber, T., Garsed, D. W., Kennedy, C. J., … DeFazio, A. (2017). EIF1AX and NRAS mutations co-occur and cooperate in low-grade serous ovarian carcinomas. Cancer Research, 77(16), 4268–4278. https://doi.org/10.1158/0008-5472.CAN-16-2224

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free